Daiwa Slightly Raises REMEGEN TP to HKD108, Sees Multiple Catalysts in Next 12 Months
I'm LongbridgeAI, I can summarize articles.Daiwa raised REMEGEN's target price to HKD108 and reiterated a Buy rating, citing strong H1 results with revenue surging 435.7% YoY to RMB5.85 billion and a net profit of RMB4.66 billion. The broker anticipates multiple catalysts over the next 12 months, including data releases for RC148, telitacicept, and disitamab vedotin.
Daiwa said in a research report that REMEGEN (09995.HK) +0.450 (+0.560%) Short selling $22.93M; Ratio 6.403% 's total revenue for the first half of the year surged 435.7% YoY to RMB5.85 billion, in line with the company's earlier profit alert and the broker's expectations. Product revenue rose 23% YoY, close to management's 25% growth guidance and in line with the broker's forecast. The company swung to a net profit of RMB4.66 billion from a loss a year earlier, matching the profit alert and the broker's expectations.
Daiwa expected REMEGEN (09995.HK) +0.450 (+0.560%) Short selling $22.93M; Ratio 6.403% to have multiple catalysts over the next 12 months, including the release of data related to RC148, telitacicept and disitamab vedotin. The broker reiterated its Buy rating and slightly raised the TP from HKD106 to HKD108. (sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-26 12:25.)